FDMT 4D Molecular Therapeutics

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

Leerink's Global Biopharma Conference 2025

Presentation Date: Tuesday, March 11, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Barclays Global Healthcare Conference 2025

Presentation Date: Wednesday, March 12, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at .

About 4DMT

4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at and follow us on .

Contacts:

Media:

Jenn Gordon

dna Communications

Investors:

Julian Pei

Head of Investor Relations and Corporate Finance



EN
19/02/2025

Underlying

FDMT4D Molecular Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 4D Molecular Therapeutics

 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase ...

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data support 4D-710’s potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease with high unmet needWebcast today at 8:00 a.m. ET with distinguished cystic fibrosis K...

December 17, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 13,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 E...

December 12, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 44th Annual J.P. Morgan Healthcare Con...

December 8, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT to Participate in 8th Annual Evercore Healthcare Conference

4DMT to Participate in 8th Annual Evercore Healthcare Conference EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 8th Annual Evercore Heal...

November 20, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Appoints Kristian Humer as Chief Financial Officer

4DMT Appoints Kristian Humer as Chief Financial Officer EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company’s financial strategy and operations, including responsibility for financial planning, capital allocation, corporate devel...

November 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch